Research Article
Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study
Table 3
Baseline demographic patient data for all RVO.
| | | Number of cases | Mean pretreatment Va LogMAR (Snellen) | Standard deviation | Mean number of treatments |
| Monotherapy | Anti-VEGF alone | 251 | 0.85 (0.14) | 0.47 | 4.45 | PPV with ILM peeling alone | 128 | 1 (0.10) | 0.49 | 1.00 | Dexamethasone implant alone | 37 | 0.68 (0.25) | 0.4 | 1.64 | Triamcinolone alone | 27 | 1.04 (0.09) | 0.48 | 1.00 |
|
Combination therapy | Anti-VEGF (1) + grid (2) | 72 | 0.80 (0.16) | 0.45 | (1) 4.58 (2) 0.88 | Anti-VEGF (1) + triamcinolone (2) | 37 | 0.96 (0.11) | 0.49 | (1) 3.16 (2) 1.04 | Anti-VEGF (1) + grid (2) + triamcinolone (3) | 27 | 0.78 (0.17) | 0.41 | (1) 2.79 (2) 1.52 (3) 1.07 | Triamcinolone (1) + PPV with ILM peeling (2) | 23 | 0.90 (0.13) | 0.47 | (1) 1.15 (2) 1.00 |
|
|
RVO: retinal vein occlusion. VEGF: vascular endothelial growth factor. PPV: pars plana vitrectomy. ILM: internal limiting membrane.
|